The Future of Drug-Resistant TB: How Do We Prevent a Nightmare? (HINT: By Treating It!) David Dowdy, MD PhD B. Frank Polk Assistant Professor of Epidemiology.

Slides:



Advertisements
Similar presentations
M. Samarkos TUBERCULOSIS IN GREECE. INTRODUCTION.
Advertisements

Generic Version: September This document has been developed by the TB CARE II project and is made possible by the generous support of the American.
A User-Friendly, Open-Source Tool to Project Impact and Costs of Diagnostic Tests for Tuberculosis David Dowdy, MD PhD June 6, 2013 Ctr for TB Research.
Christine Lubinski Vice President for Global Health Infectious Diseases Society of America April 17, 2009 Germs Go Global Tuberculosis and HIV/TB Co-Infection.
Development of extensive drug resistance in Multi-Drug resistant tuberculosis patients MSF anti-TB programmes in Abkhazia and Uzbekistan Authors: Cathy.
Factors Associated with Interruption of Treatment Among Pulmonary Tuberculosis Patients in Plateau State, Nigeria, 2011 Luka M. Ibrahim 1, P. Nguku 1,
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
U. S. Senate Briefing World TB Day Celine Gounder, MD, ScM Center for TB Research, Johns Hopkins University Director for Delivery, CREATE On behalf of.
Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.
“The more there are suffering, then the more natural their sufferings appear. Who wants to prevent the fish in the sea from getting wet? Bertolt Brecht.
Technical Advisory Group meeting, WHO/WPRO
Global Plan to Stop TB Stop TB Partnership
Disease Prevention Tuberculosis.
MDR and XDR TB Bruce A. Bush, M.D. Regional Tuberculosis Consultant
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
The Global Plan to Stop TB, (1)
How long is the duration of treatment for XDR-TB? At least 2 years (the same as MDR-TB). Doctors will monitor people with any form of confirmed drug resistant.
Eight Week Randomized Trial of Treatment with Pa-824, Moxifloxacin, and Pyrazinamide in Drug Sensitive and Multi-Drug Resistant Tuberculosis July 21, 2014.
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
1 TB/HIV Project in the Philippines Yumiko Yanase.
Global and U.S. Tuberculosis Epidemiology and Principles of Control
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
HIV Therapy for the Developing World: A Global Health Challenge Harold W. Jaffe, MD Department of Public Health University of Oxford Oxford, UK.
HIV/AIDS: A Global and Regional Perspective AIDS in Post 2015 Development Agenda.
Washington D.C., USA, July 2012www.aids2012.org Estimating the Costs and Impacts of HIV/AIDS Programs for Botswana Examples of the ART Program and.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
DOT: Can we learn from tuberculosis in the HIV field? Moïse Desvarieux, MD PhD Chaire d’Excellence ANR, Inserm UMR S 707 Associate Professor of Epidemiology,
A decentralized model of care for drug-resistant tuberculosis in a high HIV prevalence setting Cheryl McDermid, Helen Cox, Simiso Sokhela, Gilles van Cutsem,
Outcomes among patients treated for tuberculosis in Limpopo Province, South Africa, Mmakgotso Pilane, Lazarus Kuonza, Eric Maimela.
PREVENTING RELAPSE Lee B. Reichman, MD, MPH Northeast TB Controllers Meeting October 24, 2006 Princeton, New Jersey.
HIV and TB; Media for Change Natasha Rybak, MD Brown Ukraine Collaboration May 21, 2012.
Progress of the Singapore TB Elimination Programme (STEP)
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
Sanghyuk Shin, PhD Department of Epidemiology UCLA Fielding School of Public Health Aug 27, 2015 Tuberculosis and HIV Co-infection: “A Deadly Syndemic”
The Global Problem of Extensively Drug Resistant TB Peter M. Small, MD Institute for Systems Biology Bill and Melinda Gates Foundation February 17, 2008.
Epidemiologic Studies Consortium Research CTCA meeting October 22, 2010 Lisa Pascopella, PhD, MPH California Department of Health Services.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Beyond Sputum Cups and Four Drugs The Responsibility of the Practicing Clinician in the Community Control of Tuberculosis V. R. Koppaka, MD, PhD Division.
Epidemiology of Tuberculosis in African-American Population, United States Kenneth G. Castro, M.D. Assistant Surgeon General, USPHS Director,
Kow-Tong Chen, M.D., Ph.D., Hsiao-Ling Chang, Ph.D., Chu-Tzu Chen, M.P.H., and Ying-An Chen, M.P.H. Volume 23, Number 3, 2009 AIDS PATIENT CARE and STDs.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
1 [INSERT SPEAKER NAME DATE & LOCATION HERE] Ethics of Tuberculosis Prevention, Care and Control MODULE 7: GAP BETWEEN AVAILABILTY OF DRUG SUSCEPTIBILITY.
Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva, Switzerland TB prevention, care and control, : Framing global and WHO strategic.
ACHAP Economic and Social Impact Assessment. ACHAP Support Methods Epidemiological Impact Economic Impact Outline.
Modeling ‘test and treat’ for HIV in South Africa Jan AC Hontelez 1,2,3, Mark N Lurie 4, Till Bärnighausen 3,5, Roel Bakker 1 Rob Baltussen 2, Frank Tanser.
California Update : TB Epidemiology and Indicators CTCA October 22, 2010 Jennifer Flood MD MPH Chief, Surveillance and Epidemiology Tuberculosis Control.
Do we need to test for isoniazid resistance? No conflict of interest Claudia Denkinger, MD PhD McGill University, Montreal Foundation for Innovative New.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
“The more there are suffering, then the more natural their sufferings appear. Who wants to prevent the fish in the sea from getting wet? Bertolt Brecht.
Christo van Niekerk, M.D. IUATLD Meeting, Cape Town December 5, 2015 TB Alliance Ongoing Clinical Trials in DS-, MDR-and XDR-TB.
Innovative Strategies for Addressing Hepatitis C in Indian Country March 14, 2016.
Global Tuberculosis Control 2007 Did we reach the 2005 targets? Will we achieve the Millennium Development Goals?
Accutane ® Use and Epidemiology John E. La Flore, MD, MSPH Vice President, Drug Safety & Risk Management Hoffmann-La Roche Inc.
Zindoga Mukandavire Social and Mathematical Epidemiology Group London School of Hygiene and Tropical Medicine, UK Improving health worldwide
HIV and AIDS Data Hub for Asia-Pacific Review in slides Japan.
The HIV Response Where are we now?
1. Kheth’Impilo, Cape Town, South Africa
TB/ HIV CONTROL AND MANAGEMENT IN SOUTH AFRICA
Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital
Richard hayes London school of hygiene & Tropical Medicine
Global burden of HIV, viral hepatitis and TB in prisoners
Nazir Ismail CTB/NICD & WHO-SRL & UP
Brian Weir Johns Hopkins University
“The more there are suffering, then the more natural their sufferings appear. Who wants to prevent the fish in the sea from getting wet? Bertolt Brecht.
“The more there are suffering, then the more natural their sufferings appear. Who wants to prevent the fish in the sea from getting wet? Bertolt Brecht.
Vietnam Investment and Finance for TB
Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis  Dr Emily A Kendall, MD, Anthony.
Volume 393, Issue 10178, Pages (March 2019)
Presentation transcript:

The Future of Drug-Resistant TB: How Do We Prevent a Nightmare? (HINT: By Treating It!) David Dowdy, MD PhD B. Frank Polk Assistant Professor of Epidemiology Johns Hopkins Bloomberg School of Public Health March 24, 2015

The Forgotten Ones 80% of the 480,000 new cases of MDR TB globally in 2012 were not treated. – These individuals are a huge source of MDR TB transmission in the community. Treating a case of MDR TB in the USA can cost $500,000/person. – 21+ months of treatment, 8 months of daily injections, 30% of patients can expect permanent hearing loss. 88% of MDR TB patients in the US are foreign-born. – The number of these cases is on the rise. Treating more people with MDR TB will prevent transmission and death, at home and abroad.

MDR TB in Southeast Asia Primary source of MDR-TB cases in the USA What happens to people with MDR TB? – Patients are often discharged home because money/capacity to treat MDR doesn’t exist. – Most remain infectious 1-4 years later. – Mortality and “spontaneous” cure rates are no different than in the 1940s. If we treated patients diagnosed with MDR TB, what would the impact on the epidemic be?

Results from Vietnam Median duration of MDR TB infectiousness: 2.9 ( ) years – Each case generates 29 (17-57) infections and 4.1 ( ) secondary active cases

What Can We Expect if We Maintain the Status Quo? Scenarios in which MDR TB rates double in years are a reasonable expectation. – This means a doubling of MDR TB in the USA too!

MDR Treatment as Prevention: Treat people diagnosed with MDR Best estimate: Avert >50% of all cases and deaths by 2030 Flatten the epidemic curve of MDR TB

Need for R&D: Test and Treat MDR TB with an Oral 2nd-Line Regimen We can eliminate MDR TB in Southeast Asia. – The primary source of MDR TB in the USA

Conclusions Patients with untreated MDR are infectious! Treatment as Prevention of MDR TB: – Treating patients with MDR-TB can flatten the trend of the MDR TB epidemic. Improve MDR TB treatment: – Wide treatment with an oral 2 nd -line regimens can eliminate MDR TB in a Southeast Asian setting. Funding for MDR TB testing, treatment, and drug development is essential to prevent an MDR TB “nightmare”, abroad and in the USA.

Acknowledgments JHSPH TB Translational Epi and Modeling Group – Emily Kendall – Mariam Fofana – Sourya Shrestha Funding: – National Institutes of Health (T32 training grant) – B. Frank and Kathleen Polk Assistant Professorship in Epidemiology – Bill and Melinda Gates Foundation